- Home
- WIA vs CGEN Comparison
WIA vs CGEN Comparison
Compare WIA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- CGEN
- Stock Information
- Founded
- WIA 2003
- CGEN 1993
- Country
- WIA United States
- CGEN Israel
- Employees
- WIA N/A
- CGEN N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIA Finance
- CGEN Health Care
- Exchange
- WIA Nasdaq
- CGEN Nasdaq
- Market Cap
- WIA 192.9M
- CGEN 167.4M
- IPO Year
- WIA N/A
- CGEN 2000
- Fundamental
- Price
- WIA $8.39
- CGEN $1.76
- Analyst Decision
- WIA
- CGEN
- Analyst Count
- WIA 0
- CGEN 0
- Target Price
- WIA N/A
- CGEN N/A
- AVG Volume (30 Days)
- WIA 39.2K
- CGEN 181.3K
- Earning Date
- WIA 01-01-0001
- CGEN 08-05-2025
- Dividend Yield
- WIA 12.29%
- CGEN N/A
- EPS Growth
- WIA N/A
- CGEN N/A
- EPS
- WIA N/A
- CGEN N/A
- Revenue
- WIA N/A
- CGEN $27,589,000.00
- Revenue This Year
- WIA N/A
- CGEN N/A
- Revenue Next Year
- WIA N/A
- CGEN $173.80
- P/E Ratio
- WIA N/A
- CGEN N/A
- Revenue Growth
- WIA N/A
- CGEN N/A
- 52 Week Low
- WIA $7.56
- CGEN $1.13
- 52 Week High
- WIA $8.91
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- WIA 65.05
- CGEN 59.85
- Support Level
- WIA $8.25
- CGEN $1.62
- Resistance Level
- WIA $8.46
- CGEN $1.81
- Average True Range (ATR)
- WIA 0.07
- CGEN 0.08
- MACD
- WIA 0.01
- CGEN 0.00
- Stochastic Oscillator
- WIA 70.37
- CGEN 78.26
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.